• 1
    Bal DG. Cancer statistics, 2001. CA Cancer J Clin. 2001; 51: 1136.
  • 2
    Small EJ, Halabi S, Ratain MJ, et al. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of Intergroup 0159, Cancer and Leukemia Group B 9480. J Clin Oncol. 2002; 20: 33693375.
  • 3
    Curran D, Fossa S, Aaronson N, et al. Baseline quality of life of patients with advanced prostate cancer. European Organization for Research and Treatment of Cancer (EORTC), Genito-Urinary Tract Cancer Cooperative Group (GUT-CCG). Eur J Cancer. 1997; 33: 18091814.
  • 4
    Litwin MS, Lubeck DP, Stoddard ML, Pasta DJ, Flanders SC, Henning JM. Quality of life before death for men with prostate cancer: results from the CaPSURE database. J Urol. 2001; 165: 871875.
  • 5
    Penson DF, Litwin MS, Aaronson NK. Health related quality of life in men with prostate cancer. J Urol. 2003; 169: 16531661.
  • 6
    Small EJ, Meyer M, Marshall ME, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized Phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000; 18: 14401450.
  • 7
    Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999; 17: 16541663.
  • 8
    Kornblith AB, Holland JC. A model for quality-of-life research from the Cancer and Leukemia Group B: the telephone interview, conceptual approach to measurement, and theoretical framework. J Natl Cancer Inst Monogr. 1996; 20: 5562.
  • 9
    Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-Prostate instrument. Urology. 1997; 50: 920928.
  • 10
    Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002; 11: 207221.
  • 11
    Radloff LS. The CES-D: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977; 1: 385392.
  • 12
    Plutchick R, Conte HR. Self-report scales for the measurement of depression. Psychiatr Ann. 1989; 19: 367371.
  • 13
    Daut RL, Cleeland CS, Flannery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983; 14: 197210.
  • 14
    Cleeland CS. Pain control: public and physician's attitudes. In: HillCS, FieldsWS, editors. Advances in pain research and therapy. Volume 11. Drug treatment of cancer pain in a drug oriented society. New York: Raven Press, 1989: 8189.
  • 15
    Masters Steedman S, Middaugh SJ, Kee WG, Carson DS, Harden RN, Miller MC. Chronic-pain medications: equivalence levels and method of quantifying usage. Clin J Pain. 1992; 8: 204214.